Description: Following her first 100 days as the CMS Administrator, Chiquita Brooks-LaSure released her six strategic pillars for the agency. The Center for Medicaid and CHIP Services (CMCS) followed these pillars and laid out their priorities for states under the Biden-Harris administration. With these priorities established, recent 1115 submissions from several large states, including California, Massachusetts and New Jersey, may give insight to how CMS will operationalize their vision under this program authority. This session will include presentation from state policy staff who have led recent 1115 waiver proposals.

Description: Are Accelerated Underwriting (AU) programs performing as expected? As mortality experience will (hopefully) be slow to emerge, it is pivotal that we look at alternative methods of monitoring early performance. From random hold outs, to post-issue APS's, and post-issue prescription profiles, explore popular monitoring techniques and lessons learned so far. Focus on confusion matrices that provide an early indication of mortality slippage relative to fluid-based underwriting decisions. Finally, explore statistical methods to determine what constitutes credibility and identify opportunities to think about mortality slippage more robustly.

Description: Learn more about the predictive modeling that was applied to industry data for the lapse and mortality experience in the post-level term period. Novel approaches were taken to model the shock lapse, subsequent lapse, and mortality experience. Observe a demonstration of the Tableau tool, which was built to allow users to analyze data on their own.

Description: You’ve written the position papers, updated the models, and designed the required disclosures, but you may be wondering how to explain the results during interim financial reporting periods to company management as well as other stakeholders. This session will explore ways to adapt existing management reporting and offer ideas for new metrics. We will explore various methods for analyzing DAC amortization patterns, market risk benefit reserve patterns, and Liability for Future Benefits (LFPB) movements. In addition, this session will explore ways to integrate changes in LDTI with business planning and other broader business issues such as product pricing considerations and reinsurance strategy.

Description: Human longevity is one of the great success stories of the past century, and there is growing consensus that there are further gains to come. What will these future gains look like, where will they come from and how likely are they to happen. Furthermore, how do we as actuaries deal with the uncertainty when trying to predict future long-term mortality improvements more than 20 years into the future. This is one of the most important assumptions on the balance sheet that insurers and reinsurers make, so it is important to have a strong perspective on it. Our presentation will give attendees a view into some of the core components of how to assess long-term mortality improvements by looking at the cyclical nature across different countries of life expectancy. It will also deep dive into the different drivers of life expectancy over the past cycle driven largely by improved diagnosis and treatment of cardiovascular disease (CVD) and cessation of smoking, which ended in about 2010. It will then discuss how population mortality improvement has slowed and plateaued in many major countries.